Beasley Allen in Pharmaceutical News

Articles 281 to 290 of 323 in the Pharmaceutical section.

Despite Warnings, Drug Giant Took Long Path to Vioxx Recall

In May 2000, executives at Merck, the pharmaceutical giant under siege for its handling of the multibillion-dollar drug Vioxx, made a fateful decision.

Prescription for Trouble

When the pharmaceutical giant Merck pulled its blockbuster pain medication Vioxx off the market in late September, it became the largest prescription drug recall in history.

Despite Warnings, Drug Giant took long path to Vioxx Recall

In May 2000, executives at Merck, the pharmaceutical giant under siege for its handling of the multi-billion-dollar drug Vioxx, made a fateful decision.

Former Pell City Resident to Appear on '60 Minutes'

Some of Pell City’s citizens may recognize a familiar face if they turn on 60 minutes Sunday night.

Lawyers prepare for litigation against Merck over Vioxx

Representatives of both the drugmaker Merck and the FDA will be on Capitol Hill next week to answer safety questions about Merck's drug Vioxx.

Courses Share info On Basics of Billion Dollar Tort

On the September morning Merck pulled its blockbuster pain medicine Vioxx from the market, a group of lawyers was busy taking deposition from the drug maker’s former chief medical officer.

Lawyers bone up on Vioxx Liability

On the September morning Merck pulled its blockbuster pain medicine Vioxx from the market, a group of lawyers was busy taking a deposition from the drug maker's former chief medical officer.

Lawyers Meet to Discuss Scope of Vioxx Litigation

Lawyers meeting on Tuesday to discuss Vioxx litigation say pending lawsuits will show that Merck & Co, Inc. (MRK.N) was aware of the arthritis drug’s risks before it was taken off the market.

Lawyers meet to discuss scope of Vioxx Litigation.

Lawyers meeting to discuss Vioxx litigation say pending lawsuits will show that Merck & Co. Inc. was aware of the arthritis drug's risks before it was taken off the market.

Vioxx Shockwaves Rock Merck

Company officials shocked the world Sept. 30 with its immediate withdrawal ofVioxx, a COX-2 inhibitor, from the world market citing patient concern. The arthritis and acute pain drug was the company's best selling product, generating $2.5 billion sales in 2003, 11 percent of Merck's total revenues